Stem cell therapy vs controlPerformance status – change in functional class (NYHA) · DCM (non‐ischaemic)1 finding from 1 reviewStem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 398 participantsLow